@article{ATM23427,
author = {Chong-Kin Liam},
title = {Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer},
journal = {Annals of Translational Medicine},
volume = {7},
number = {3},
year = {2019},
keywords = {},
abstract = {Although the majority of patients with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)- sensitizing mutations experience good initial response to first‑generation (erlotinib, gefitinib) and second-generation (afatinib, dacomitinib) EGFR-TKIs, they invariably suffer disease progression either due to a pharmacodynamic resistance to the EGFR-TKI or a pharmacokinetic failure resulting in central nervous system (CNS) progression (1-3).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/23427}
}